PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?
Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.
If not the deadliest, the novel coronavirus (COVID-19) is certainly the most serious contagious disease to have crossed continents in modern times. One of the biggest challenges is screening en-masse for the detection of infectious individuals. Today’s current methods are rudimentary (measuring only temperature) or very expensive and time-consuming (swab test).
A joint venture between Spinview and VR Media Technology has created an effective weapon against coronavirus. Using a proven successful matrix of sensors, PandemiCam can identify a wide range of symptoms to indicate infection, in seconds. Once the device is installed, unlimited tests can be performed without having to rely on consumable materials. The device is able to operate en-masse and report to a central server for infection monitoring and tracking. Accuracy is much higher than with non-contact thermometers, as the system can scan thousands of measurements per second across an entire spectrum of sensors, including, but going well beyond, only temperature. COVID-19 is known to affect physiological parameters such as temperature, respiration, hydration, sweating, flushing and coughing. PandemiCam is a non-invasive multisensory device, which is designed to collect information from multiple sensors to ‘read’ the COVID-19 symptom parameters in every person it scans. PandemiCam combines the use of mathematics and artificial intelligence (AI) with pre-existing sensors into one revolutionary scanning unit enabling widespread screening with ease. The collected data is fused together by the system and feed through AI, to provide accurate and fast detection of infectious people with far greater clarity than any single parameter test available today. The complex scanning system can help authorities across the globe limit the spread of COVID-19, assisting in the management of precious healthcare resources in real-time. Where current single parameter tests such as temperature have to be measured individually, PandemiCam is able to screen groups of people and even scan at a distance for the safety necessitated by this particular disease. Against a city grid, PandemiCam allows for the real-time mapping of symptoms. Quick identification of hotspots allows for localised restrictions and resource allocations, reducing financial damage and human danger. Dr Katarina Gospic, Director of Neuroscience at Spinview, said: "Our invention can give real-time information about the general health status of a population. This is data can contribute to a healthier world. The more frequently we can screen for infection in the case of corona, the better we will be at limiting spread. Healthcare systems could be provided with the number of infectious people in real-time, which would enable them to plan resources. Screening is crucial to winning the battle against corona."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance